

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT

THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF BREXPIRAZOLE MICROSpheres

Recently, Zhuhai Livzon Microsphere Technology Co., Ltd.* (珠海市麗珠微球科技有限公司) ("**Zhuhai Livzon Microsphere**"), a wholly-owned subsidiary of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "**Company**"), has received the Notice of Drug Clinical Trial Approval (Notice No.: 2026LP00935) issued by the National Medical Products Administration ("**NMPA**"), approving the conduct of clinical trials for Brexpiprazole Microspheres for Injection (hereinafter referred to as "**this product**") for the treatment of schizophrenia in adults. Details are as follows:

BASIC INFORMATION ABOUT THE DRUG

Drug name: Brexpiprazole Microspheres for Injection

Dosage form: Injection

Registration classification: Class 2.2 modified new chemical drug

Applied indication: For the treatment of schizophrenia in adults

Approval conclusion: In accordance with the Drug Administration Law of the People's Republic of China (《中華人民共和國藥品管理法》) and related regulations, upon review, the application for Brexpiprazole Microspheres for Injection accepted on 7 January 2026 complies with relevant

requirements for drug registration. Approval is granted to conduct clinical trials for the treatment of schizophrenia in adults.

DRUG DEVELOPMENT AND RELATED CONDITIONS

Brexipiprazole Microspheres for Injection is a sustained-release microsphere formulation independently developed by the Company, and is a new generation treatment for schizophrenia. This product exerts its therapeutic effects through partial agonism of dopamine D2 and 5-HT1A receptors and antagonism of norepinephrine receptors, demonstrating superior performance on multiple safety indicators compared to other drugs of the same generation.

This product employs a long-acting sustained-release design, with a proposed dosing regimen of once-monthly intramuscular injection, which may improve patient medication adherence, reduce relapse risk, address the clinical challenges of low treatment adherence and high relapse rates in schizophrenia patients, and meet the needs for long-term maintenance therapy.

Currently, oral brexpiprazole formulations have been approved globally for multiple psychiatric indications, while no brexpiprazole long-acting formulation has been approved for marketing. This product is a modified new drug developed to fill this clinical gap.

As at the date of this announcement, the cumulative direct research and development expenses incurred for Brexpiprazole Microspheres for Injection amount to approximately RMB 7.5264 million.

MARKET SITUATION OF DRUG

According to the website of the Center for Drug Evaluation (CDE) of NMPA, as at the date of this announcement, no brexpiprazole long-acting formulation has been approved for marketing in China.

RISK WARNING

In accordance with the relevant laws and regulations governing drug registration in China, following the receipt of the Notice of Drug Clinical Trial Approval, the drug is still required to undergo clinical trials and must be subject to review and approval by the NMPA before it can be manufactured and marketed. Due to the inherent nature of drug research and development, the

progression from clinical trials to commercial production and market launch is a lengthy process involving multiple stages, and may be subject to various uncertainties. There are inherent uncertainties regarding the progress and outcomes of the clinical trials, as well as the future competitive landscape for the product. The Company will fulfill its information disclosure obligations in a timely manner based on the progress of research and development, and investors are advised to pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
26 March 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

** For identification purpose only*